Giuseppe Ciaramella, Ph.D.
About Giuseppe Ciaramella, Ph.D.
Giuseppe Ciaramella, Ph.D., is a seasoned biochemist with over 20 years of experience in drug discovery and has held significant roles at major pharmaceutical companies including Moderna and Pfizer.
Giuseppe Ciaramella, Ph.D. Education and Expertise
Giuseppe Ciaramella holds a Ph.D. in Biochemistry and Molecular Biology from University College London. With over 20 years of experience in drug discovery, he has a robust background in both small molecules and biologics. His extensive expertise spans key leadership roles in several major pharmaceutical companies, including Pfizer, Merck, AstraZeneca, Boehringer Ingelheim, and Moderna Therapeutics.
Professional Background of Giuseppe Ciaramella, Ph.D.
Giuseppe Ciaramella has held significant positions in various reputable pharmaceutical companies. At Moderna Therapeutics, he served as Chief Scientific Officer (CSO) of the Infectious Diseases division, where he contributed to the development of some of the first mRNA vaccines dosed in humans. He has also been Vice President and Head of Collaborative Research at Boehringer Ingelheim and spent 14 years in discovery leadership roles at Pfizer in the UK. His professional experience also includes tenures at AstraZeneca and Merck.
Giuseppe Ciaramella, Ph.D. Achievements in Pharmaceuticals
One of Giuseppe Ciaramella's notable contributions is his work on the anti-HIV drug Maraviroc (Selzentry TM), which won the USA Prix Galien for Best Pharmaceutical in 2008. He has also contributed to the development of multiple clinical candidates in both small molecules and biologics. His work in mRNA vaccine development at Moderna marked a significant milestone, as these were among the first mRNA vaccines to be dosed in humans.
Giuseppe Ciaramella, Ph.D. Industry Associations
Giuseppe Ciaramella is actively involved in professional communities through his memberships in the Infectious Diseases Society of America (IDSA) and the American Society of Gene Therapy (ASGT). These affiliations reflect his commitment to staying engaged with ongoing developments and contributing to his field.